Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03818685
Title Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard

triple-receptor negative breast cancer


Ipilimumab + Nivolumab


Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.